Montelukast Sodium Tablet, Coated
Product Images NDC 68084-875

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Montelukast Sodium (NDC 68084-875). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ahp87501

Montelukast Sodium 10 mg coated tablet, brown square with rounded edges. One side is embossed with the letter 'R' and the other side shows the imprint '725'. This oral prescription drug is labeled by American Health Packaging.*

FDA Label Image

Blister

Montelukast Sodium 10 mg coated tablets label for oral use, intended for adults 15 years and older. The label is issued by American Health Packaging and includes the lot number 123456 and expiration date 03/16. The image shows multiple identical rectangular labels arranged in a sheet format.*

FDA Label Image

Carton

Montelukast Sodium 10 mg coated tablets label from American Health Packaging. The label indicates the product is for oral use and intended for adults 15 years and older. The package contains 100 tablets (10 x 10) with Rx only designation. Additional text includes pharmacist dispensing instructions, active ingredient information, storage conditions, and distributor details.*

FDA Label Image

Figure1 (Figure 1)

A line graph depicting change in height (cm) over weeks on treatment for three groups: Montelukast Sodium 5 mg, Beclomethasone 336 mcg, and Placebo. The x-axis shows treatment duration in weeks from -19 to 56, and the y-axis shows change in height ranging from -3 to 7 cm. All groups start near zero and show an increasing trend in height over time, with Montelukast and Beclomethasone generally showing similar growth above placebo.*

FDA Label Image

Figure2 (Figure 2)

A line graph showing mean percent change from baseline over 15 weeks in treatment for Montelukast Sodium and placebo groups. The x-axis represents weeks in treatment, and the y-axis shows mean percent change from baseline. Montelukast Sodium group shows a higher increase compared to placebo. A washout period is indicated after week 12.*

FDA Label Image

Structure (Structure)

Chemical structure of montelukast sodium depicted as a molecular diagram showing its atomic connections, including chlorine, sulfur, and sodium components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.